Details of the Drug

General Information of Drug (ID: DMFMW5C)

Drug Name
MVA-BN Breast
Synonyms MVA-BN-pRo (TN)
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 1 [1]
Cross-matching ID
TTD ID
D08GFN

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostate specific antigen (KLK3) TTS78AZ KLK3_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Prostate
The Studied Disease Prostate cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostate specific antigen (KLK3) DTT KLK3 2.01E-01 -0.04 -0.09
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00629057) A Safety Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer. U.S. National Institutes of Health.
2 Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44.